Memantine: a NMDA receptor antagonist that improves memory by restoration of homeostasis in the glutamatergic system--too little activation is bad, too much is even worse - PubMed (original) (raw)

Review

Memantine: a NMDA receptor antagonist that improves memory by restoration of homeostasis in the glutamatergic system--too little activation is bad, too much is even worse

Chris G Parsons et al. Neuropharmacology. 2007 Nov.

Abstract

The neurotransmitter glutamate activates several classes of metabotropic receptor and three major types of ionotropic receptor--alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA), kainate and N-methyl-D-aspartate (NMDA). The involvement of glutamate mediated neurotoxicity in the pathogenesis of Alzheimer's disease (AD) is finding increasing scientific acceptance. Central to this hypothesis is the assumption that glutamate receptors, in particular of the NMDA type, are overactivated in a tonic rather than a phasic manner. Such continuous, mild, chronic activation ultimately leads to neuronal damage/death. Additionally, impairment of synaptic plasticity (learning) may result not only from neuronal damage per se but may also be a direct consequence of this continuous, non-contingent NMDA receptor activation. Complete NMDA receptor blockade has also been shown to impair neuronal plasticity, thus, both hypo- and hyperactivity of the glutamatergic system leads to dysfunction. Memantine received marketing authorization from the EMEA (European Medicines Agency) for the treatment of moderate to severe AD in Europe and was subsequently also approved by the FDA (Food and Drug Administration) for use in the same indication in the USA. Memantine is a moderate affinity, uncompetitive NMDA receptor antagonist with strong voltage-dependency and fast kinetics. This review summarizes existing hypotheses on the mechanism of action (MOA) of memantine in an attempt to understand how the accepted interaction with NMDA receptors could allow memantine to provide both neuroprotection and reverse deficits in learning/memory by the same MOA.

PubMed Disclaimer

Cited by

The role of the tripartite glutamatergic synapse in the pathophysiology of Alzheimer's disease.
Rudy CC, Hunsberger HC, Weitzner DS, Reed MN. Rudy CC, et al. Aging Dis. 2015 Mar 10;6(2):131-48. doi: 10.14336/AD.2014.0423. eCollection 2015 Mar. Aging Dis. 2015. PMID: 25821641 Free PMC article. Review.
Disabling Uncompetitive Inhibition of Oncogenic IDH Mutations Drives Acquired Resistance.
Lyu J, Liu Y, Gong L, Chen M, Madanat YF, Zhang Y, Cai F, Gu Z, Cao H, Kaphle P, Kim YJ, Kalkan FN, Stephens H, Dickerson KE, Ni M, Chen W, Patel P, Mims AS, Borate U, Burd A, Cai SF, Yin CC, You MJ, Chung SS, Collins RH, DeBerardinis RJ, Liu X, Xu J. Lyu J, et al. Cancer Discov. 2023 Jan 9;13(1):170-193. doi: 10.1158/2159-8290.CD-21-1661. Cancer Discov. 2023. PMID: 36222845 Free PMC article.
Reduction of advanced tau-mediated memory deficits by the MAP kinase p38γ.
Ittner A, Asih PR, Tan ARP, Prikas E, Bertz J, Stefanoska K, Lin Y, Volkerling AM, Ke YD, Delerue F, Ittner LM. Ittner A, et al. Acta Neuropathol. 2020 Sep;140(3):279-294. doi: 10.1007/s00401-020-02191-1. Epub 2020 Jul 29. Acta Neuropathol. 2020. PMID: 32725265
Hippocampal alterations in glutamatergic signaling during amyloid progression in AβPP/PS1 mice.
Hascup KN, Findley CA, Sime LN, Hascup ER. Hascup KN, et al. Sci Rep. 2020 Sep 2;10(1):14503. doi: 10.1038/s41598-020-71587-6. Sci Rep. 2020. PMID: 32879385 Free PMC article.
Toward refining Alzheimer's disease into overlapping subgroups.
Hascup ER, Hascup KN. Hascup ER, et al. Alzheimers Dement (N Y). 2020 Aug 27;6(1):e12070. doi: 10.1002/trc2.12070. eCollection 2020. Alzheimers Dement (N Y). 2020. PMID: 32885025 Free PMC article.

Memantine: a NMDA receptor antagonist that improves memory by restoration of homeostasis in the glutamatergic system--too little activation is bad, too much is even worse - PubMed (original) (raw)